Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two Part Phase 1 Multicenter Open-label Study of DKN-01 Given Intravenously. Part A: Dose-Escalation in Patients With Multiple Myeloma or Advanced Solid Tumors. Part B: Expansion Cohort in Patients With Relapsed / Refractory Non-Small Cell Lung Cancer (NSCLC)

NCT01457417 is registered in ClinicalTrials.gov with Leap Therapeutics, Inc. as lead sponsor.

NCT NCT01457417
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01457417 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two Part Phase 1 Multicenter Open-label Study of DKN-01 Given Intravenously. Part A: Dose-Escalation in Patients With Multiple Myeloma or Advanced Solid Tumors. Part B: Expansion Cohort in Patients With Relapsed / Refractory Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
Leap Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2012
Completion date
December 31, 2013
Enrollment
32 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, non-small cell lung cancer, solid tumors